| Outcome Measures: |
Primary: Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days., Start of treatment up to 12 hours. | Secondary: Time to maximum concentration (Tmax) of metformin after 3.5 days of treatment., Start of Treatment up to 30 hours.|Maximum concentration (Cmax) of metformin after 3.5 days of treatment., Start of Treatment up to 30 hours.|Area under the concentration versus time curve of metformin from 0 to the time of the last measurable (positive) concentration (AUC0-t) after 3.5 days of treatment., Start of Treatment up to 30 hours.|Area under the concentration versus time curve of metformin from 0 to infinity (AUC0-inf) after 3.5 days of treatment., Start of Treatment up to 30 hours.|Terminal half-life (t1/2) of metformin after 3.5 days of treatment., Start of Treatment up to 30 hours.|Clearance (CL/F) of metformin after 3.5 days of treatment., Start of Treatment up to 30 hours.|Apparent volume of distribution (VzF) of metformin after 3.5 days of treatment., Start of Treatment up to 30 hours.|Time to maximum concentration (Tmax) of HRS9531., Start of Treatment up to 504 hours.|Maximum concentration (Cmax) of HRS9531., Start of Treatment up to 504 hours.|Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration (AUC0-t)., Start of Treatment up to 30 hours.|Area under the concentration versus time curve of HRS9531 from 0 to infinity (AUC0-inf)., Start of Treatment up to 504 hours.|Terminal half-life (t1/2) of HRS9531., Start of Treatment up to 504 hours.|Clearance (CL/F) of HRS9531., Start of Treatment up to 504 hours.|Apparent volume of distribution (VzF) of HRS9531., Start of Treatment up to 504 hours.|Incidence and severity of adverse events., Screening period up to 42 days.
|
